16 September 2026 note archive · Item
Regular human insulin U100 (Humulin R / Actrapid): review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Regular human insulin U100 (Humulin R / Actrapid)
Scope and findings: Added in the second discovery pass. Established short-acting human insulin. Its slower meal timing differs from rapid analogues; presentation-specific withdrawals in Australia do not mean all regular human insulin is discontinued worldwide. Numerical claims are tied to the cited product specifications or named study, and editorial scores do not represent measured comparative performance.
Primary sources checked:
- Humulin R U100 US prescribing information
- TGA current insulin supply changes
- Lilly current medicines catalogue
Limits: Scope is the specific claims documented in the new record. Local stock, payer rules, every hardware variant and unreported head-to-head outcomes are not verified. Regulatory status, manufacturer marketing and clinical performance are distinct.